INSIGHT: China Health Insurance Sector Entering Fast Track
This article was originally published in PharmAsia News
A complex mix of diverse factors and trends is shaping the development of China’s private and public health insurance markets, with global firms including Munich Re now looking to tap into some of the opportunities. But with health schemes still accounting less than 3% of the overall insurance market in the country, there is a long way to go.
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.